Top

Published in:

01-02-2002 | Review

Science review: Key inflammatory and stress pathways in critical illness – the central role of the Toll-like receptors

Author: Bruce Beutler, Professor

Published in: Critical Care | Issue 1/2003

Abstract

A pure reductionist approach can sometimes be used to solve an exceptionally complicated biologic problem, and sepsis is nothing if not complicated. A serious infection promptly leads to changes in many aspects of host physiology, including alterations in circulation, metabolism, renal, hepatic, and neuroendocrine function; all of these changes happen at once, and each influences one another. It is difficult to tease apart a problem of this sort, if only because the systems affected are so profoundly interactive. The key to understanding sepsis, insofar as we do understand it at present, was found in the use of genetic tools to study the very earliest events that take place at the interface of the pathogen and the host. The continued application of both forward and reverse genetic methods, in both mammals and insects, is steadily revealing the central biochemical events that occur during infection.

Wirthmueller U, Dewald B, Thelen M, Schafer MK, Stover C, Whaley K, North J, Eggleton P, Reid KB, Schwaeble WJ: Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J Immunol 1997, 158: 4444-4451.PubMed

Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, Reid KB, Jensenius JC: A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997, 386: 506-510. 10.1038/386506a0CrossRefPubMed

Vorup-Jensen T, Jensenius JC, Thiel S: MASP-2, the C3 convertase generating protease of the MBLectin complement activating pathway. Immunobiology 1998, 199: 348-357.CrossRefPubMed

Thiel S, Petersen SV, Vorup-Jensen T, Matsushita M, Fujita T, Stover CM, Schwaeble WJ, Jensenius JC: Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBL-associated serine proteases 1 and 2, and the MBL-associated protein MAp19. J Immunol 2000, 165: 878-887.CrossRefPubMed

Dahl MR, Thiel S, Matsushita M, Fujita T, Willis AC, Christensen T, Vorup-Jensen T, Jensenius JC: MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001, 15: 127-135. 10.1016/S1074-7613(01)00161-3CrossRefPubMed

Liu C, Xu Z, Gupta D, Dziarski R: Peptidoglycan recognition proteins: a novel family of four human innate immunity pattern recognition molecules. J Biol Chem 2001, 276: 34686-34694. 10.1074/jbc.M105566200CrossRefPubMed

Liu C, Gelius E, Liu G, Steiner H, Dziarski R: Mammalian peptidoglycan recognition protein binds peptidoglycan with high affinity, is expressed in neutrophils, and inhibits bacterial growth. J Biol Chem 2000, 275: 24490-24499. 10.1074/jbc.M001239200CrossRefPubMed

Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ: Structure and function of lipopolysaccharide binding protein. Science 1990, 249: 1429-1431.CrossRefPubMed

Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249: 1431-1433.CrossRefPubMed

10.

Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert SM: Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996, 4: 407-414.CrossRefPubMed

11.

Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A: Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985, 161: 984-995.CrossRefPubMed

12.

Beutler B, Greenwald D, Hulmes JD, Chang M, Pan Y-CE, Mathison J, Ulevitch R, Cerami A: Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985, 316: 552-554.CrossRefPubMed

13.

Beutler B, Milsark IW, Cerami A: Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985, 135: 3972-3977.PubMed

14.

Beutler B, Milsark IW, Cerami A: Passive immunization against cachectin/tumor necrosis factor (TNF) protects mice from the lethal effect of endotoxin. Science 1985, 229: 869-871.CrossRefPubMed

15.

Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJI, Zentella A, Albert JD, Shires GT, Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 1986, 234: 470-474.CrossRefPubMed

16.

Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ: Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 1983, 80: 5397-5401.PubMedCentralCrossRefPubMed

17.

Beutler B, Tkacenko V, Milsark IW, Krochin N, Cerami A: The effect of interferon-gamma on cachectin expression by mononuclear phagocytes: reversal of the lps-d (endotoxin resistance) phenotype. J Exp Med 1986, 164: 1791-1796.CrossRefPubMed

18.

Pfeffer K, Matsuyama T, Kündig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Krönke M, Mak TW: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993, 73: 457-467.CrossRefPubMed

19.

Car BD, Eng VM, Schnyder B, Ozmen L, Huang S, Gallay P, Heumann D, Aguet M, Ryffel B: Interferon gamma receptor deficient mice are resistant to endotoxic shock. J Exp Med 1994, 179: 1437-1444.CrossRefPubMed

20.

Butler LD, Layman NK, Cain RL, Riedl PE, Mohler KM, Bobbitt JL, Belagajie R, Sharp J, Bendele AM: Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention. Clin Immunol Immunopathol 1989, 53: 400-421.CrossRefPubMed

21.

Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990, 348: 550-552. 10.1038/348550a0CrossRefPubMed

22.

Waage A, Espevik T: Interleukin 1 potentiates the lethal effect of tumor necrosis factor α/cachectin in mice. J Exp Med 1988, 167: 1987-1992.CrossRefPubMed

23.

Beutler B, Cerami A: Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 1985, 135: 3969-3971.PubMed

24.

Dayer J-M, Zavadil-Grob C, Ucla C, Mach B: Induction of human interleukin 1 mRNA measured by collagenase and prostaglandin E2-stimulating activity in rheumatoid synovial cells. Eur J Immunol 1984, 14: 898-901.CrossRefPubMed

25.

Stanger BZ, Leder P, Lee T-H, Kim E, Seed B: RIP: a novel protein containing a death domain that interacts with Fas/Apo-1 (CD95) in yeast and causes cell death. Cell 1995, 81: 513-523.CrossRefPubMed

26.

Hsu H, Xiong J, Goeddel DV: The TNF receptor 1-associated protein TRADD signals cell death and NF-kappaB activation. Cell 1995, 81: 495-504.CrossRefPubMed

27.

Hsu HL, Shu HB, Pan MG, Goeddel DV: TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996, 84: 299-308.CrossRefPubMed

28.

Ting AT, Pimentel-Muiños FX, Seed B: RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J 1996, 15: 6189-6196.PubMedCentralPubMed

29.

Rothe M, Wong SC, Henzel WJ, Goeddel DV: A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994, 78: 681-692.CrossRefPubMed

30.

Erickson SL, De Sauvage FJ, Kikly K, Carver-Moore K, Pitts-Meek S, Gillett N, Sheehan KCF, Schreiber RD, Goeddel DV, Moore MW: Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994, 372: 560-563.CrossRefPubMed

31.

Darnell JE Jr, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264: 1415-1421.CrossRefPubMed

32.

Poltorak A, He X, Smirnova I, Liu M-Y, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg MA, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282: 2085-2088. 10.1126/science.282.5396.2085CrossRefPubMed

33.

Poltorak A, Ricciardi-Castagnoli P, Citterio A, Beutler B: Physical contact between LPS and Tlr4 revealed by genetic complementation. Proc Natl Acad Sci USA 2000, 97: 2163-2167. 10.1073/pnas.040565397PubMedCentralCrossRefPubMed

34.

Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT: Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000, 105: 497-504.PubMedCentralCrossRefPubMed

35.

Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A: The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999, 401: 811-815. 10.1038/44605CrossRefPubMed

36.

Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S: Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999, 11: 443-451.CrossRefPubMed

37.

Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408: 740-745. 10.1038/35047123CrossRefPubMed

38.

Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410: 1099-1103. 10.1038/35074106CrossRefPubMed

39.

Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413: 732-738. 10.1038/35099560CrossRefPubMed

40.

Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S: Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998, 9: 143-150.CrossRefPubMed

41.

Kawai T, Adachi O, Ogawa T, Takeda K, Akira S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999, 11: 115-122.CrossRefPubMed

42.

Whitmer JD, Koslovsky JS, Bahler M, Mercer JA: Chromosomal location of three unconventional myosin heavy chain genes in the mouse. Genomics 1996, 38: 235-237. 10.1006/geno.1996.0622CrossRefPubMed

43.

Poltorak A, Smirnova I, He XL, Liu MY, Van Huffel C, McNally O, Birdwell D, Alejos E, Silva M, Du X, Thompson P, Chan EKL, Ledesma J, Roe B, Clifton S, Vogel SN, Beutler B: Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 1998, 24: 340-355. 10.1006/bcmd.1998.0201CrossRefPubMed

44.

Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K: Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002, 3: 667-672.PubMed

45.

Hoebe K, Du X, Goode J, Mann N, Beutler B: LPS2: a new locus required for responses to lipopolysaccharide revealed by germline mutagenesis and p[henotypic screening. J Endotoxin Res 2002, in press.

46.

Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA: The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86: 973-983.CrossRefPubMed

47.

Michel T, Reichhart JM, Hoffmann JA, Royet J: Drosophila Toll is activated by Gram-positive bacteria through a circulating peptidoglycan recognition protein. Nature 2001, 414: 756-759. 10.1038/414756aCrossRefPubMed

48.

Tauszig-Delamasure S, Bilak H, Capovilla M, Hoffmann JA, Imler JL: Drosophila MyD88 is required for the response to fungal and Gram-positive bacterial infections. Nat Immunol 2002, 3: 91-97. 10.1038/ni747CrossRefPubMed

49.

Hoffmann JA, Reichhart JM: Drosophila innate immunity: an evolutionary perspective. Nat Immunol 2002, 3: 121-126. 10.1038/ni0202-121CrossRefPubMed

50.

Heppner G, Weiss DW: High susceptibility of strain A mice to endotoxin and endotoxin-red blood cell mixtures. J Bacteriol 1965, 90: 696-703.PubMedCentralPubMed

51.

Sultzer BM: Genetic control of leucocyte responses to endotoxin. Nature 1968, 219: 1253-1254.CrossRefPubMed

52.

O'Brien AD, Rosenstreich DL, Scher I, Campbell GH, MacDermott RP, Formal SB: Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene. J Immunol 1980, 124: 20-24.PubMed

53.

Rosenstreich DL, Weinblatt AC, O'Brien AD: Genetic control of resistance to infection in mice. CRC Crit Rev Immunol 1982, 3: 263-330.

54.

Hagberg L, Hull R, Hull S, McGhee JR, Michalek SM, Svanborg Eden C: Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect Immun 1984, 46: 839-844.PubMedCentralPubMed

55.

Woods JP, Frelinger JA, Warrack G, Cannon JG: Mouse genetic locus Lps influences susceptibility to Neisseria meningitidis infection. Infect Immun 1988, 56: 1950-1955.PubMedCentralPubMed

56.

Macela A, Stulik J, Hernychova L, Kroca M, Krocova Z, Kovarova H: The immune response against Francisella tularensis live vaccine strain in Lpsⁿ and Lps^d mice. FEMS Immunol Med Microbiol 1996, 13: 235-238. 10.1016/0928-8244(95)00110-7CrossRefPubMed

57.

Watson J, Kelly K, Largen M, Taylor BA: The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol 1978, 120: 422-424.PubMed

58.

Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, Itie A, Li S, Penninger JM, Wesche H, Ohashi PS, Mak TW, Yeh WC: Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 2002, 416: 750-756. 10.1038/nature736CrossRefPubMed

59.

Geppert TD, Whitehurst CE, Thompson P, Beutler B: LPS signals activation of TNF biosynthesis through the RAS/RAF-1/MEK/MAPK pathway. Mol Med 1994, 1: 93-103.PubMedCentralPubMed

60.

Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, Woodgett JR: The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994, 369: 156-160. 10.1038/369156a0CrossRefPubMed

61.

Han J, Lee JD, Bibbs L, Ulevitch RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994, 265: 808-811.CrossRefPubMed

62.

Herrera-Velit P, Reiner NE: Bacterial lipopolysaccharide induces the association and coordinate activation of p53/56lyn and phosphatidylinositol 3-kinase in human monocytes. J Immunol 1996, 156: 1157-1165.PubMed

63.

Hawkins LD, Ishizaka ST, McGuinness P, Zhang H, Gavin W, DeCosta B, Meng Z, Yang H, Mullarkey M, Young DW, Yang H, Rossignol DP, Nault A, Rose J, Przetak M, Chow JC, Gusovsky F: A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity. J Pharmacol Exp Ther 2002, 300: 655-661. 10.1124/jpet.300.2.655CrossRefPubMed

Title: Science review: Key inflammatory and stress pathways in critical illness – the central role of the Toll-like receptors
Author: Bruce Beutler, Professor
Publication date: 01-02-2002
Publisher: BioMed Central
Published in: Critical Care / Issue 1/2003
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc1828

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Science review: Key inflammatory and stress pathways in critical illness – the central role of the Toll-like receptors

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2003

The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is norepinephrine rather than dopamine

Glucose–insulin–potassium infusion in sepsis and septic shock: no hard evidence yet

Recently published papers: A number of treatment controversies

Isabel

Severity of Illness Online

15th Annual Congress of the European Society of Intensive Care Medicine, 29 September–2 October 2002, Barcelona, Spain: Clinical research to improve outcome